$STRO
SUTRO BIOPHARMA, INC.

2021 Q1 Form 10-Q Financial Statement

#000156459021025155 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $14.66M $7.152M
YoY Change 104.98% -17.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.11M $8.710M
YoY Change 27.55% 12.82%
% of Gross Profit
Research & Development $22.56M $17.62M
YoY Change 28.05% 16.07%
% of Gross Profit
Depreciation & Amortization $1.291M $1.099M
YoY Change 17.47% -3.34%
% of Gross Profit
Operating Expenses $33.67M $17.62M
YoY Change 91.09% -23.04%
Operating Profit -$19.01M
YoY Change
Interest Expense -$11.35M -$420.0K
YoY Change 2602.38% -2200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$30.36M -$19.60M
YoY Change 54.9% 37.54%
Income Tax
% Of Pretax Income
Net Earnings -$30.36M -$19.60M
YoY Change 54.93% 37.51%
Net Earnings / Revenue -207.09% -273.98%
Basic Earnings Per Share -$0.84
Diluted Earnings Per Share -$661.3K -$0.84
COMMON SHARES
Basic Shares Outstanding 45.89M 23.10M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $251.2M $115.4M
YoY Change 117.68% -32.36%
Cash & Equivalents $55.82M $43.57M
Short-Term Investments $195.4M $71.80M
Other Short-Term Assets $7.500M $3.000M
YoY Change 150.0% 15.38%
Inventory
Prepaid Expenses
Receivables $7.200M $9.100M
Other Receivables $0.00 $0.00
Total Short-Term Assets $266.0M $127.5M
YoY Change 108.63% -27.76%
LONG-TERM ASSETS
Property, Plant & Equipment $14.80M $9.500M
YoY Change 55.79% -4.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $74.60M $14.20M
YoY Change 425.35% 3.65%
Other Assets $3.100M $2.700M
YoY Change 14.81% 20.81%
Total Long-Term Assets $92.50M $26.40M
YoY Change 250.38% 1.7%
TOTAL ASSETS
Total Short-Term Assets $266.0M $127.5M
Total Long-Term Assets $92.50M $26.40M
Total Assets $358.5M $153.9M
YoY Change 132.94% -23.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.900M $5.800M
YoY Change 1.72% 70.84%
Accrued Expenses $4.500M $2.900M
YoY Change 55.17% 15.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $22.70M $32.00M
YoY Change -29.06% 2.79%
LONG-TERM LIABILITIES
Long-Term Debt $24.70M $24.20M
YoY Change 2.07% 184.71%
Other Long-Term Liabilities $3.900M $15.60M
YoY Change -75.0% -51.4%
Total Long-Term Liabilities $28.60M $39.80M
YoY Change -28.14% -1.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.70M $32.00M
Total Long-Term Liabilities $28.60M $39.80M
Total Liabilities $51.20M $71.80M
YoY Change -28.69% 0.14%
SHAREHOLDERS EQUITY
Retained Earnings -$258.2M -$215.3M
YoY Change 19.93% 39.58%
Common Stock $297.4M
YoY Change 4.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $307.3M $82.09M
YoY Change
Total Liabilities & Shareholders Equity $358.5M $153.9M
YoY Change 132.98% -24.0%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$30.36M -$19.60M
YoY Change 54.93% 37.51%
Depreciation, Depletion And Amortization $1.291M $1.099M
YoY Change 17.47% -3.34%
Cash From Operating Activities -$30.43M -$18.73M
YoY Change 62.43% -7.0%
INVESTING ACTIVITIES
Capital Expenditures -$2.380M $763.0K
YoY Change -411.93% 176.45%
Acquisitions
YoY Change
Other Investing Activities -$119.4M $42.40M
YoY Change -381.49% -154.5%
Cash From Investing Activities -$121.7M $41.64M
YoY Change -392.36% -153.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.826M 15.70M
YoY Change -88.37% -3528.38%
NET CHANGE
Cash From Operating Activities -30.43M -18.73M
Cash From Investing Activities -121.7M 41.64M
Cash From Financing Activities 1.826M 15.70M
Net Change In Cash -150.3M 38.61M
YoY Change -489.42% -139.12%
FREE CASH FLOW
Cash From Operating Activities -$30.43M -$18.73M
Capital Expenditures -$2.380M $763.0K
Free Cash Flow -$28.05M -$19.50M
YoY Change 43.87% -4.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
41644000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5559000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4486000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
378182000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12935000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.846
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.732
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.849
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.773
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.010
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.016
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46103606
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46103606
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 150
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45752116
CY2020Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2813000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45752116
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1291000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-496000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14660000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7152000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22562000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17619000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19009000
CY2020Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
641000
CY2021Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-10689000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45907590
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23197971
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-129000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-137000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30488000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19732000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
332048000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1360000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
873000
CY2021Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
407000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3952000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-30359000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
307338000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
97789000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
646000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2707000
CY2020Q1 stro Warrants Issued During Period Value In Connection With Debt Refinancing
WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing
619000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-137000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19595000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
82085000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-30359000
CY2021Q1 stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
2376000
CY2021Q1 stro Remeasurement Of Liability Awards
RemeasurementOfLiabilityAwards
11000
CY2020Q1 stro Remeasurement Of Liability Awards
RemeasurementOfLiabilityAwards
-7000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3952000
CY2021Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-10689000
CY2020Q1 stro Payments To Acquire Equipment And Leasehold Improvements
PaymentsToAcquireEquipmentAndLeaseholdImprovements
763000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1360000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
407000
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
646000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15702000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38605000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
43580000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
134000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
255000
CY2020Q1 stro Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
600000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
15000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56690000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43580000
CY2021Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2003-04-21
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258200000
CY2021Q1 stro Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
294900000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55818000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43565000
CY2021Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
872000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
292845000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
65000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
324845000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
131000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
324973000
CY2021Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
74600000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2021Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
84600000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
14700000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2021Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
12100000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2021Q1 stro Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
100000
CY2020Q4 stro Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
200000
CY2020Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
200000
CY2021Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
200000
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
200000
CY2021Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0807
CY2020Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0809
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
100000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Remainder Of Fiscal Year
LesseeOperatingSubleaseLiabilityPaymentsRemainderOfFiscalYear
4780000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due Next Twelve Months
LesseeOperatingSubleaseLiabilityPaymentsDueNextTwelveMonths
5183000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due Year Two
LesseeOperatingSubleaseLiabilityPaymentsDueYearTwo
6310000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due Year Three
LesseeOperatingSubleaseLiabilityPaymentsDueYearThree
7476000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due Year Four
LesseeOperatingSubleaseLiabilityPaymentsDueYearFour
7737000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due After Year Four
LesseeOperatingSubleaseLiabilityPaymentsDueAfterYearFour
16296000
CY2021Q1 stro Lessee Operating Sublease Liability Payments Due
LesseeOperatingSubleaseLiabilityPaymentsDue
47782000
CY2021Q1 stro Potential Financial Benefit Base Rent Abatement
PotentialFinancialBenefitBaseRentAbatement
5200000
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10718984
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8331103
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1900000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
76000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.13
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.94
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3952000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2707000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257834
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
257834
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4445
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4445
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
8890
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
266724
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
266724
CY2021Q1 stro Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
79000
CY2019Q4 stro Liability Attributable To Call Option Plan
LiabilityAttributableToCallOptionPlan
109000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-30359000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19595000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45907590
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23197971
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8205947
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6065721

Files In Submission

Name View Source Status
0001564590-21-025155-index-headers.html Edgar Link pending
0001564590-21-025155-index.html Edgar Link pending
0001564590-21-025155.txt Edgar Link pending
0001564590-21-025155-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stro-10q_20210331.htm Edgar Link pending
stro-10q_20210331_htm.xml Edgar Link completed
stro-20210331.xsd Edgar Link pending
stro-20210331_cal.xml Edgar Link unprocessable
stro-20210331_def.xml Edgar Link unprocessable
stro-20210331_lab.xml Edgar Link unprocessable
stro-20210331_pre.xml Edgar Link unprocessable
stro-ex101_9.htm Edgar Link pending
stro-ex311_8.htm Edgar Link pending
stro-ex312_6.htm Edgar Link pending
stro-ex321_10.htm Edgar Link pending
stro-ex322_7.htm Edgar Link pending